| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6182608 | Gynecologic Oncology | 2016 | 9 Pages |
Abstract
NR4A1 is highly expressed in a subset of HGSOC samples from patients that have a worse progression free survival. Studies to target NR4A1 for therapeutic intervention should include HGSOC.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Evan Delgado, Michelle M. Boisen, Robin Laskey, Rui Chen, Chi Song, Jad Sallit, Zachary A. Yochum, Courtney L. Andersen, Matthew J. Sikora, Jacob Wagner, Stephen Safe, Esther Elishaev, Adrian Lee, Robert P. Edwards, Paul Haluska, George Tseng,